ArticleIJID regions2025
Molecular characterization and antimicrobial resistance of
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to elucidate the molecular characteristics and antimicrobial resistance of Methods: A total of 45 isolates obtained from adults (aged 41-98 years) with IPD between 2017 and 2023 were analyzed for serotype, sequence type (ST), and antimicrobial susceptibility. Results: Of the 45 isolates, serotype 3-ST180 (24.4%) was the most prevalent, followed by 23A-ST338/ST5242 (13.3%); 23F-ST242/ST1437/ST3543 (8.9%); and 6D-ST282, 15A-ST63, 35B-ST558, and 34-ST1439/ST7388 (6.7% each), which collectively accounted for 73.4% of all isolates. The proportion of the pneumococcal conjugate vaccine (PCV) 13, PCV20, and 23-valent polysaccharide vaccine (PPSV23) serotypes were 44.5%, 46.7%, and 44.5%, respectively. The rate of non-susceptibility to penicillin was 24.4%, and the majority (n = 10 of 11, 90.9%) were also non-susceptible to erythromycin and tetracycline. The multidrug resistance rate for the non-PCV20/PPSV23 serotype was 83.3%, which was higher than the 71.4% for the vaccine serotypes. Among the non-PCV20/PPSV23 serotypes, 23A, 6D, 15A, 35B, and 6E (genetic variant of 6B) showed multidrug resistance with non-susceptibility to penicillin. Conclusions: The present study revealed that the non-vaccine serotypes in IPD among adults were associated with a high prevalence of non-susceptibility to antimicrobial agents, suggesting the need for continuous surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.